{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/johnson--johnsons-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-us-fda-priority-review-as-potential-first-in-class-egfr--and-met-targeted-subcutaneous-treatment-for-advanced-head-and-neck-cancer-302838985.html", "message": "News view counter 858045 successfully enlarged"}